Infex’s novel AMR drug candidate MET-X receives FDA QIDP designation
Infex Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted qualified…
January 4, 2023 - 2 minutes
Infex Therapeutics has announced that the U.S. Food and Drug Administration (FDA) has granted qualified…
A new anti-virulence therapy, RESP-X, treating Pseudomonas aeruginosa (Pa) infections in non-cystic fibrosis bronchiectasis (NCFB)…